Journey Medical Corp. DERM 深 滬
已收盤 04-02 16:00:00 美东时间
4.95
+0.310
+6.68%
華盛通- 最 高5.02
- 今 開4.46
- 成交量 32.58万股
- 最 低 4.46
- 昨 收 4.64
- 總市值 1.35亿
- 52周最高 9.555
- 市盈率 靜 --
- 換手率 1.19%
- 52周最低 4.31
- 委 比 -92.44%
- 總股本 2733.07万
- 歷史最高 10.20
- 量 比 0.48
- 振 幅 12.07%
- 歷史最低 1.02
- 每 手 1
- 風險率 0.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
HC Wainwright & Co. Reiterates Buy on Journey Medical, Maintains $13 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Journey Medical (NASDAQ:DERM) with a Buy and maintains $13 price target.
03-26 17:33
Journey Medical Q4 EPS $(0.04) Beats $(0.06) Estimate, Sales $16.079M Miss $18.863M Estimate
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 31.03 percent. This is a 150 percent decrease over earnings of $0.08 per share from the
03-26 04:20
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell • Chewy (NYSE:CHWY) is expected to report q...
03-25 19:11
Journey Medical Files $3.75M At-The-Market Common Stock Offering With B. Riley And Lake Street
3,750,000 SHARES OF COMMON STOCKWe have entered into an At Market Issuance Sales Agreement (the "Sales Agreement") with B. Riley Securities, Inc. ("B. Riley") and Lake Street Capital Markets, LLC ("Lake Street") (each,
01-24 05:13
Journey Medical Q3 EPS $(0.09) Misses $(0.04) Estimate, Sales $17.631M Miss $18.854M Estimate
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.04) by 143.24 percent. This is a 25 percent increase over losses of $(0.12) per share from
2025-11-13 05:02
Insights into Journey Medical's Upcoming Earnings
Journey Medical (NASDAQ:DERM) will release its quarterly earnings report on Wed...
2025-11-12 02:03
Journey Medical Corporation Releases Pooled Phase 3 Data From Its MVOR-1 And MVOR-2 Trials Evaluating DFD-29 Demonstrating Emrosi's Statistical Superiority Over Oracea And Placebo In Achieving Investigator's Global Assessment Treatment Success And Reducing Inflammatory Lesion Counts
FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea
2025-10-24 20:33
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
FDA-approved Emrosi (DFD-29), a modified-release minocycline formulation, has demonstrated superior efficacy in treating inflammatory lesions of rosacea in adults compared to both placebo and doxycycline in two Phase 3 clinical trials. Emrosi achieved statistically significant higher Investigator’s Global Assessment (IGA) success rates (62.7%) and greater reductions in inflammatory lesion counts (-19.2) compared to Oracea (39.0%, -14.8) and place...
2025-10-24 12:30
Journey Medical Corporation to Participate in September 2025 Investor Conferences
Journey Medical Corporation’s CEO Claude Maraoui to attend two September 2025 investor conferences in New York City. The events include H.C. Wainwright’s Global Investment Conference on Sept 8 and Lake Street Capital’s BIG9 Conference on Sept 11. Both are in NYC with fireside chat and 1x1 meetings format. The company focuses on marketing FDA-approved dermatological products and currently markets eight branded prescription drugs.
2025-09-03 12:30
